A clinical trial of iron supplementation for people with heart failure
Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial (IRON-MAN)
Paul R Kalra (lead researcher)
Glasgow, University of
Start date: 01 March 2016 (Duration 5 years)
Iron is needed for many processes in our bodies to work, including enabling our muscles to function correctly. People with heart failure frequently have low iron levels, which worsens their symptoms of shortness of breath and fatigue, their ability to exercise, their quality of life and their life expectancy.
Some small clinical trials have found that intravenous iron replacement can improve the symptoms and quality of life for people with heart failure in the short term. But we don’t know if correcting iron deficiency benefits patients with chronic heart failure in the long term, and whether it improves life expectancy and keeps them out of hospital.
Dr Paul Kalra and his team at Portsmouth Hospitals NHS Trust have been awarded a BHF grant to carry out a four year long clinical trial to study the effects of intravenous iron in people with heart failure. They will recruit patients from across the country with chronic heart failure and iron deficiency and will determine whether treatment with intravenous iron is safe, if it reduces the need for hospitalisation due to heart failure, and reduces death. They will also determine whether it improves quality of life and is cost effective.
If this large study shows that iron supplementation makes a difference, it could help to change the clinical management of patients with chronic heart failure.
||01 March 2016
< back to search results